Abstract
Yang H, Li L, Li X, Ma Y, Yang Y, Cao D. Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm, prospective phase II trial. Ther Adv Med Oncol. 2024;16. doi:10.1177/17588359241292264
In this article, there were errors in the “Methods and analysis” section of the abstract, Figure 1, and the “Intervention” subsection of the main text regarding the treatment cycle duration and the dosage of fluorouracil.
The errors and their corresponding corrections are detailed below:
In the
“Eligible participants will receive cadonilimab at a dosage of 6 mg/kg on day 1 of each 21-day cycle combined with intravenous liposomal irinotecan at a dosage of 70 mg/m² for 90 min on day 1 plus leucovorin at a dosage of 400 mg/m² for 30 min on day 1 and fluorouracil at a dosage of 400 mg/m² for 46 h every 2 weeks”
has been corrected to:
“Eligible participants will receive cadonilimab at a dosage of 6 mg/kg on day 1 of each 14-day cycle combined with intravenous liposomal irinotecan at a dosage of 70 mg/m² for 90 min on day 1 plus leucovorin at a dosage of 400 mg/m² for 30 min on day 1 and fluorouracil at a dosage of 2400 mg/m² for 46 h every 2 weeks.”
In
In the
“Eligible participants will receive cadonilimab at a dose of 6 mg/kg on the first day of a 21-day cycle combined with intravenous liposomal irinotecan at a dose of 70 mg/m² for 90 min on the first day, along with leucovorin at a dose of 400 mg/m² for 30 min on the first day and fluorouracil at a dose of 400 mg/m² for 46 h every 2 weeks.”
has been corrected to:
“Eligible participants will receive cadonilimab at a dose of 6 mg/kg on the first day of a 14-day cycle combined with intravenous liposomal irinotecan at a dose of 70 mg/m² for 90 min on the first day, along with leucovorin at a dose of 400 mg/m² for 30 min on the first day and fluorouracil at a dose of 2400 mg/m² for 46 h every 2 weeks.”